1
|
Crowell LE, Lu AE, Love KR, Stockdale A, Timmick SM, Wu D, Wang Y(A, Doherty W, Bonnyman A, Vecchiarello N, Goodwine C, Bradbury L, Brady JR, Clark JJ, Colant NA, Cvetkovic A, Dalvie NC, Liu D, Liu Y, Mascarenhas CA, Matthews CB, Mozdzierz NJ, Shah KA, Wu SL, Hancock WS, Braatz RD, Cramer SM, Love JC. On-demand manufacturing of clinical-quality biopharmaceuticals. Nat Biotechnol 2018; 36:nbt.4262. [PMID: 30272677 PMCID: PMC6443493 DOI: 10.1038/nbt.4262] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 08/27/2018] [Indexed: 12/18/2022]
Abstract
Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification. We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulation to a final dosage form of recombinant biopharmaceuticals. We demonstrate that InSCyT can accelerate process development from sequence to purified drug in 12 weeks. We used integrated design to produce human growth hormone, interferon α-2b and granulocyte colony-stimulating factor with highly similar processes on this system and show that their purity and potency are comparable to those of marketed reference products.
Collapse
Affiliation(s)
- Laura E. Crowell
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Amos E. Lu
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Kerry R. Love
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Alan Stockdale
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Steven M. Timmick
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
- GlaxoSmithKline, King of Prussia, Pennsylvania, USA
| | - Di Wu
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - Yu (Annie) Wang
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - William Doherty
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Alexandra Bonnyman
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Nicholas Vecchiarello
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
| | - Chaz Goodwine
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
| | | | - Joseph R. Brady
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - John J. Clark
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Biogen, Cambridge, Massachusetts, USA
| | - Noelle A. Colant
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
- Department of Biochemical Engineering, University College London, London, England
| | - Aleksandar Cvetkovic
- Pall Life Sciences, Westborough, Massachusetts, USA
- Sanofi, Framingham, Massachusetts, USA
| | - Neil C. Dalvie
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Diana Liu
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | - Yanjun Liu
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - Craig A. Mascarenhas
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Catherine B. Matthews
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Nicholas J. Mozdzierz
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Kartik A. Shah
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
| | | | - William S. Hancock
- Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston,
Massachusetts, USA
| | - Richard D. Braatz
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| | - Steven M. Cramer
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York,
USA
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York,
USA
| | - J. Christopher Love
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts,
USA
| |
Collapse
|